| Aspect | The Analyst's Note on "TELX" | Search Results on Telix Pharmaceuticals (TLX) |
|---|---|---|
| Sector | Automotive, Transportation | Biotechnology / Radiopharmaceuticals |
| Key Focus | Software, time-to-market, competition with Chinese OEMs | Developing diagnostic and therapeutic products for cancer |
| Recent Financials | Not specified | Strong financial performance, with Q3 2025 unaudited revenue of ~$206M (up 53% YoY) and increased FY2025 revenue guidance to $800M-$820M. Full-year 2024 revenue was $783.2M AUD. |
| Stock Performance | ~33% decline in FY25, expensive valuation at 35x Sep-27 EPS | Shares have declined significantly from a 52-week high of ~$30.36. The stock trades at a high P/E ratio (e.g., 471x TTM P/E), indicating a high-growth, high-valuation profile. |
| Analyst Rating | Downgraded to "HOLD" from "REDUCE" | No direct analyst rating found in the provided search results. |
It is possible that the search results did not capture the correct company because:
- Different Company: The analyst might be covering a different company with the ticker "TELX" that is not in the financial databases referenced by the search results.
- Ticker Confusion: The note could be referencing a different listing for Telix Pharmaceuticals, which trades as
TLX.AXon the ASX andTLXon NASDAQ. - Limited Information: Specific analyst reports on a particular company are often not available in general search results.
💡 How to Proceed
If you are sure the analyst note refers to Telix Pharmaceuticals, the conflicting information on its business sector is critical. It would be best to:
- Clarify the company name by checking with the source of the note.
- Search directly for the full analyst report using the brokerage firm's name and the report title.
If you have the correct company name or can provide a different ticker symbol, I can help you look for more targeted information.